Background: Women with node-positive breast cancer are at high risk for recurrence. We evaluate the impact of approximated tumor subtype and response to chemotherapy on long-term outcomes in a node-positive cohort receiving neoadjuvant chemotherapy. Methods: ACOSOG Z1071 enrolled cT0-4N1-2 breast cancer patients treated with neoadjuvant chemotherapy from 2009 to 2011. Factors impacting breast cancer-specific survival (BCSS) and overall survival (OS) were analyzed. Results: Median follow-up of 701 eligible patients was 4.1 years (0.4-6.5). Ninety patients (12.8%) died from breast cancer. Approximated subtype and chemotherapy response were significantly associated with BCSS and OS (P < 0.0001). BCSS and OS were highest in patients who achieved pathologic complete response (pCR) (P < 0.0001 and P < 0.0001, respectively). Five-year BCSS was highest in human epidermal growth factor receptor 2 (HER2)-positive disease [95.8%; 95% confidence interval (CI): 87.7-98.6], followed by hormone receptor-positive/HER2-negative (80.4%; 95% CI: 73.2-85.9) and lowest in triple-negative (TNBC) (74.8%; 95% CI: 66.6-81.2; P < 0.0001). Similar patterns were seen in OS. In TNBC (n ¼ 174), 5-year BCSS was higher in patients with pCR versus residual disease (89.8%; 95% CI: 78.8-95.3 vs 65.8%; 95% CI: 54.5-74.9; P ¼ 0.0013). In hormone receptor-positive/HER2-negative (n ¼ 318) disease, BCSS was 100% in patients with pCR and 78.3% (95% CI: 70.4-84.3) in those with residual disease (P ¼ 0.018). In HER2-positive disease (n ¼ 204) there was no difference between pCR and residual disease (96.0%; 95% CI: 83.6-99.1 vs 95.8%; 95% CI: 81.4-99.1; P ¼ 0.77). Conclusions: In node-positive breast cancer patients treated with neoadjuvant chemotherapy, BCSS and OS were associated with approximated subtype and chemotherapy response and were lowest in TNBC patients with residual disease. Five-year BCSS was > 95% in HER2-positive disease independent of chemotherapy response.
N odal staging in breast cancer remains important because it provides prognostic information and stratifies patients into higher and lower risk groups with respect to recurrence and mortality due to breast cancer. In patients with biopsy-confirmed node-positive disease at initial presentation, the use of chemotherapy prior to surgical intervention (neoadjuvant chemotherapy) is often considered. Delivery of chemotherapy to patients in the neoadjuvant setting is associated with several advantages; increased rates of breastconserving surgery, downstaging of disease in the regional nodal basins, and the opportunity to assess response to therapy. [1] [2] [3] [4] [5] [6] Eradication of disease from the breast and the lymph nodes, pathologic complete response (pCR), has been shown to be associated with improved survival when compared with the presence of residual disease after chemotherapy. 7 Invasive breast cancers are routinely classified into approximated subtypes based on the status of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) on immunohistochemistry studies of the primary tumor. Tumors overexpressing HER2 are known to be biologically more aggressive; however, currently available HER2-targeted therapies are highly effective and have been shown to improve outcomes when patients receive HER2-targeted therapy with chemotherapy. In hormone receptor (HR)-positive disease (ER positive and/or PR positive), endocrine therapy is an important component of systemic treatment and is usually given in the adjuvant setting. For triplenegative breast cancer (TNBC), defined as ER negative, PR negative, and HER2 negative, chemotherapy is the only current systemic therapy option. Studies evaluating administration of chemotherapy in the neoadjuvant setting have shown that response rates to chemotherapy vary by tumor subtype [8] [9] [10] [11] and that pCR is associated with prognosis. 7, 12, 13 In this study, we report the 5-year breast cancer-specific survival (BCSS) and overall survival (OS) rates in women with node-positive breast cancer who were treated with neoadjuvant chemotherapy and enrolled on the American College of Surgeons Oncology Group (ACOSOG) Z1071 trial. We also examine the impact of approximated subtype on response to chemotherapy and survival.
METHODS
ACOSOG Z1071 was a prospective clinical trial that enrolled 756 patients with clinical cT0-4, N1-2 breast cancer treated with neoadjuvant chemotherapy across 136 institutions from 2009 to From the 2011. The primary endpoint of the trial, false negative rate of sentinel lymph node surgery, was previously reported. 14 All patients underwent axillary dissection. Data regarding clinical stage at presentation, ER, PR, and HER2 status, chemotherapy delivered, surgical procedure, pathologic stage, and use of adjuvant treatment were collected prospectively on the case report forms at the treating institution and reported to the ACOSOG (Alliance) Statistics and Data Center. Breast cancer approximated subtype was defined by HR status from combined ER and PR status and HER2 status as follows: HR positive, HER2-negative (ER positive and/or PR positive, and HER2-negative), HER2-positive (HER2 3þ by immunohistochemistry or amplified by FISH or ISH), and triple negative (ER < 1%, PR < 1%, and HER2-negative). Pathologic complete response was defined as no residual invasive disease in the breast or axillary lymph nodes.
The extent of disease in the surgical specimen was evaluated by the pathologist at the local site and residual disease was staged using the yp-stage designation of the 7th edition of the American Joint Committee on Cancer (AJCC) staging system. Additionally, reporting on the residual cancer burden (RCB) was requested on the case report forms and, where available, analysis of the RCB class was performed. Calculation of RCB provides a standardized procedure for pathologic evaluation of postneoadjuvant specimens. Educational materials with detailed instructions and an online calculator to determine RCB are posted on a publically available website. 15, 16 Each participant signed an IRB-approved, protocolspecific informed consent in accordance with federal and institutional guidelines.
Statistical Considerations
Pathologic response rates were summarized with binomial estimates and 95% confidence intervals (CIs). Comparisons of categorical baseline variables were made among groups with a x 2 test and with a t test or ANOVA as appropriate for continuous variables. BCSS and OS were measured from the time of surgery and estimated with a Kaplan-Meier estimator. BCSS events were defined as deaths due to breast cancer. Patients were censored if they died from another cause or if they were alive at the time of analysis. Overall survival events were defined as death due to any cause and patients who were alive at the time of analysis were censored. Univariable and multivariable Cox models were used to generate hazard ratios with 95% CIs. The multivariable model was adjusted for known prognostic variables. Statistical analyses were conducted by the Alliance Statistics and Data Center. Data quality was ensured by review of data by the Alliance Statistics and Data Center and by the study chair following Alliance policies. The database used for these analyses was locked October 5, 2016. The trial was registered on clinicaltrials.gov with trial identifier NCT00881361.
RESULTS
Of 756 women enrolled on the ACOSOG Z1071 trial, 701 patients met eligibility criteria. Median follow-up was 4.1 years (range 0.4-6.5). Patient and tumor characteristics are summarized in Table 1 . As reported previously, 17 pCR rate varied by approximated tumor subtype, being highest in HER2-positive disease and lowest in HR-positive/HER2-negative disease. All 204 patients with HER2-positive disease were treated with a regimen that included chemotherapy and HER2-targeted therapy. Among the 442 patients with HR-positive disease (regardless of HER2 status), 369 (92.5%) received endocrine therapy in the adjuvant setting.
At the time of analysis, 107 patients had died, 90 of breast cancer and 17 from other causes. Table 2 . On univariable analysis, approximated tumor subtype was associated with BCSS and OS (P < 0.0001); patients with HER2-positive disease had the best BCSS and OS followed by those with HR-positive, HER2-negative disease. The worst BCSS and OS were observed in TNBC patients. Response in the breast and the nodes to neoadjuvant chemotherapy were strongly associated with BCSS (P < 0.0001) and OS (P < 0.0001); increasing pathologic tumor category at surgery and increasing pathologic nodal category at surgery were both strongly associated with reduced BCSS and OS. Clinical tumor category at presentation, use of adjuvant radiation, and type of primary tumor surgery were not statistically significantly associated with BCSS or OS. On multivariable analysis, which included clinical tumor category, approximated tumor subtype, pathologic tumor category, pathologic nodal category, surgical procedure, and use of adjuvant radiation in the model, the statistically significant factors for BCSS and OS were approximated tumor subtype and pathologic nodal category and for OS pathologic tumor category was also significant.
Approximated Tumor Subtype
We further evaluated the association of BCSS and OS with approximated tumor subtype. BCSS was best in patients with HER2-positive tumors, with a 5-year BCSS of 95.8% (95% CI: 87.7-98.6), followed by patients with HR-positive/HER2-negative disease who had 5-year BCSS of 80.4% (95% CI: 73.2-85.9). Patients with TNBC had a 5-year BCSS of 74.8% (95% CI: 66.6-81.2). The observed differences in BCSS among the approximated subtypes were statistically significant (P < 0.0001).
Similarly, statistically significant differences were observed in OS (P < 0.0001), with the highest 5-year OS observed in patients with HER2-positive tumors at 93.5% (95% CI: 86.2-97.0), followed by HR-positive/HER2-negative disease with 5-year OS of 76.6% (95% CI: 69.0-82.6). The lowest 5-year OS was observed in patients with triple-negative disease at 73.1% (95% CI: 64.9-79.6).
Dividing the patients with HER2-positive tumors into HER2-positive/HR-positive and HER2-positive/HR-negative, the rate of pCR was significantly higher in HER2-positive/HR-negative disease at 53.6% compared with HER2-positive/HR-positive disease where the pCR rate was 39.2% (P ¼ 0.042); however, there was no difference in 5-year OS between HER2-positive/HR-negative at 95.6% (95% CI: 81.7-99.0) and HER2-positive/HR-positive at 92.1% (95% CI: 80.7-96.9, P ¼ 0.56). Similarly, there was no difference in 5-year BCSS between HER2-positive/HR-negative at 95.6% (95% CI: 81.7-99.0) and HER2-positive/HR-positive at 95.8% (95% CI: 80.8-99.1, P ¼ 0.68).
Pathologic Response
BCSS and OS were highest in patients with pCR compared with those with residual disease ( Fig. 1A ; P < 0.0001 and P < 0.0001, respectively). The 5-year BCSS was best in patients who experienced a pCR (94.7%; 95% CI: 89.2-97.4), followed by patients with residual disease in the breast only (eradication of nodal disease) (93.7%; 95% CI: 85.3-97.3) and those with residual disease in the lymph nodes only (eradication of disease in the breast) (92.2%; 95% CI: 70.5-98.1). The worst BCSS was observed in patients with residual disease in both the breast and lymph nodes (74.8%; 95% CI: 68.0-80.3).
In the subset of 532 patients where the RCB class was available, RCB class was associated with BCSS and OS (both P < 0.0001, Fig. 1B ). RCB-III had significantly poorer survival compared with RCB 0/I/II; for OS, the hazard ratio for RCB-III (vs 0/I/II) was 5.22 (3.32, 8.21) , P < 0.0001 and for BCSS, the hazard ratio for RCB-III (vs 0/I/II) was 4.95 (3.03, 8.07), P < 0.0001.
Impact of Pathologic Response by Approximated Subtype
As previously reported, pCR rates varied by approximated tumor subtype. Patients with HER2-positive disease had the highest pCR rate (45.1%), followed by TNBC (42.0%). HR-positive/HER2-negative disease had the lowest pCR rate (11.5%), P < 0.0001.
Comparing all patients who achieved a pCR, 5-year BCSS was high, with rates of 100% for HR-positive/HER2-negative disease and 96.0% (95% CI: 83.6-99.1) for HER2-positive, however was lower at 89.8% (95% CI: 78.8-95.3) for TNBC (P ¼ 0.018). There was no statistically significant difference in OS between the approximated subtypes in patients with a pCR (P ¼ 0.086, Table 3 ).
In patients with residual disease after chemotherapy, 5-year BCSS was significantly higher in patients with HER2-positive disease at 95.8% (95% CI: 81.4-99.1) compared with patients with HR-positive/HER2-negative disease at 78.3% (95% CI: 70.4-84.3) and those with TNBC at 65.8% (95% CI: 54.5-74.9). These differences were statistically significant, (P < 0.0001). Similar patterns of OS by approximated tumor subtype were seen in patients with residual disease (P < 0.0001).
An evaluation of the impact of pCR on BCSS by approximated tumor subtype yielded a significant difference in patients with TNBC (n ¼ 174) between those with a pCR, with a 5-year BCSS of 89.8% (95% CI: 78.8-95.3) compared with those with residual disease, with 5-year BCSS of 65.8% (95% CI: 54.5-74.9), P ¼ 0.0013 (Fig. 2) . In the 204 patients with HER2-positive disease, there was no statistically significant difference in BCSS between those patients who achieved a pCR, with 96.0% (95% CI: 83.6-99.1) 5-year BCSS; compared with those with residual disease, with 95.8% (95% CI: 81.4-99.1) 5-year BCSS, P ¼ 0.77. In the 323 patients with HR-positive/HER2-negative breast cancer, the proportion of patients achieving a pCR was low (11.5%), and there were no BCSS events seen in the patients with a pCR. The 5-year BCSS rate of patients with residual disease was 78.3% (95% CI: 70.4-84.3). In patients with HR-positive/HER2-negative disease, the 5-year OS rates were 97.1% (95% CI 80.9-99.6) in patients with a pCR and 74.4% (95% CI 66.2-80.9) in patients with residual disease (P ¼ 0.033). BCSS and OS by RCB class for each approximated tumor subtype are shown in Figure 3 . As RCB class increases, BCSS and OS decrease in HR-positive/HER2-negative and TNBC.
DISCUSSION
In this prospective clinical trial of biopsy-proven node-positive breast cancer patients treated with neoadjuvant chemotherapy, we have confirmed that BCSS and OS were associated with approximated tumor subtype and response to chemotherapy. The highest 5-year survival rates were seen in the patients with HR-positive/HER2-negative disease who achieved a pCR, although this was a small group of patients and HR-positive tumors are known to have a longer time to relapse. Five-year BCSS was > 95% in patients with HER2-positive disease treated with HER2-targeted therapy, regardless of extent of residual disease after neoadjuvant chemotherapy. The poorest survival was seen in TNBC patients with residual disease. Pathologic complete response was a strong indicator of outcome in TNBC and HR-positive/HER2-negative disease.
Assessment of pCR is valuable information for estimating survival as patients with pCR have improved survival compared with those patients with residual disease. This finding has been consistent across studies that have documented that disease response correlates with survival. 7,13,18 -20 Previous studies, however, have shown that dichotomous distinction of pCR and residual disease is a suboptimal prognostic surrogate. Evaluation of location of residual disease showed that residual disease in the nodes was associated with a worse prognosis compared with residual disease in the breast alone. The greatest difference was seen between those with residual disease in either the breast or nodes only compared with those patients with residual disease in both the breast and nodes. Estimation of extent of disease by Residual Cancer Burden has been proposed as an informative method for the assessment of extent of residual disease after neoadjuvant chemotherapy, since RCB class has been shown to correlate with survival. 15,21 -23 As demonstrated in our data, and in keeping with previous reports, the RCB class provides additional discrimination, in particular to identify those patients with the poorest outcome, as identified by RCB class III. RCB-III is a group of patients at significantly higher risk of relapse and identifies a patient group that may benefit from further systemic therapy and an area to focus additional research. The impact of additional systemic therapy in patients with high volume residual disease remains an area under investigation and data from prospective trials are needed to address this question. One prospective randomized study in patients with HER2-negative breast cancer with residual disease after neoadjuvant chemotherapy showed that adjuvant capecitabine resulted in a better recurrence-free survival. 24 The survival curves for RCB-I and II did not demonstrate significant separation in the Z1071 cohort. It may be that longer follow-up is needed to demonstrate differences between these RCB classes.
TNBC is known to be an aggressive subtype of breast cancer, with poor outcomes compared with other tumor subtypes. 25 This is likely due to the heterogeneity of the disease and the lack of availability of targeted therapy for this subtype. Consistent with other studies, we found that patients with TNBC who achieved a pCR had a significantly better BCSS and OS compared with those with FIGURE 1. Breast cancer-specific survival and overall survival by: (A) pathologic complete response (pCR) versus any residual disease, and (B) residual cancer burden class (n ¼ 532). residual disease. 26 In fact, patients with TNBC who experienced a pCR had 5-year BCSS and OS in keeping with the other tumor subtypes. It is reassuring that such patients with ''chemosensitive'' TNBC have an excellent outcome, such that additional systemic therapy may not be necessary. This highlights one of the advantages of delivery of chemotherapy in the neoadjuvant setting, as it provides outcome information to the treating physicians and patients early in the course of treatment and can be an opportunity to tailor treatment recommendations based on response. Patients with chemotherapyresistant TNBC are at the highest risk of recurrence and death due to breast cancer and therefore multiple studies are evaluating the role of additional systemic therapy in these patients. One such study is SWOG 1418 which randomizes patients with TNBC who have residual disease after neoadjuvant chemotherapy to pembrolizumab versus no additional therapy.
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HER2-positive breast cancer is a biologically aggressive subtype of breast cancer and early studies demonstrated poor survival in these patients. However, as understanding of HER2-positive disease advanced and HER2-targeted therapies are now routinely administered, the survival rates have dramatically improved. Studies have shown that the use of HER2-targeted therapy, in addition to chemotherapy, in the neoadjuvant setting resulted in high rates of pathologic complete response. 8, 9, [28] [29] [30] [31] [32] [33] During the time that the ACOSOG Z1071 trial was conducted, patients with HER2-positive disease treated in the neoadjuvant setting routinely received chemotherapy and trastuzumab.
Currently, treatment for HER2-positive breast cancer in the neoadjuvant setting can include more than 1 HER2-targeted agent in addition to chemotherapy (such as both trastuzumab and pertuzumab) and results in even higher pCR rates. 10, 12, 31, 34 The pCR rate observed in patients with HER2-positive disease in Z1071 was 45%. Interestingly, the 5-year OS and BCSS were not impacted by the presence of residual disease in this cohort of patients. A prior small study that included 53 patients with HER2-positive disease demonstrated favorable locoregional recurrence rates regardless of response to neoadjuvant chemotherapy. 26 The findings from this study and the current study are in contrast to multiple previous studies that have shown that in patients with HER2-positive disease pCR is associated with improved survival compared with those with residual disease. 7, 11, 13, 33, 35 A meta-analysis of studies by Cortazar et al 7 which included 1989 patients with HER2-positive disease showed a significant difference in event-free survival between the 586 patients who achieved a pCR and the 1403 patients with residual disease. The finding that there was no difference in survival outcomes in Z1071 in the HER2-positive patients with or without pCR may be due to the relatively small sample size and the relatively short follow-up time. With the addition of pertuzumab, and possibly other HER2-targeted agents in the future, outcomes for patients with HER2-positive disease may continue to improve. Current clinical trials are addressing the role of HER2-targeted therapies without chemotherapy. FIGURE 2. Breast cancer-specific survival and overall survival comparing patients with a pathologic complete response (pCR) to those with residual disease in triple-negative breast cancer, HER2-positive breast cancer, and hormone receptor (HR)-positive/HER2-negative breast cancer.
Hormone receptor-positive/HER2-negative breast cancer is considered a less aggressive subtype and breast cancer recurrences often occur much later in the course of the disease, with risk of recurrence remaining elevated beyond 10 years. 36 The presence of a target (estrogen receptor) for adjuvant systemic therapy along with the availability of endocrine therapy that is reasonably well tolerated has led to lower rates of breast cancer events in this patient population. Rates of pCR in the patients with HR-positive/HER2-negative disease were low at 11.5%. This is consistent with other studies that have previously shown lower pCR rates in HR-positive disease. 7, 13, 37 Additionally, the number of breast cancer recurrences or deaths in the patients who achieved a pCR was so small that statistical comparison of the impact of pCR on outcome was limited. Since these patients are treated with adjuvant endocrine therapy for 5 years and in some instances 10 years after surgery, they remain at risk for future breast cancer events for over 10 years. 36 One limitation of the Z1071 trial is that luminal A tumors could not be distinguished from luminal B tumors based on the available information.
In HR-positive/HER2-negative disease, alternative strategies for treatment are being explored and utilized in the clinical practice, in particular the use of neoadjuvant endocrine therapy to assess the endocrine responsiveness of the tumor. Patients with an excellent response to neoadjuvant endocrine therapy may be candidates to avoid chemotherapy. 38 Additionally, prognostic indicators such as the 21-gene recurrence score are being used in patients with ERpositive disease, both in node-negative and in some cases in nodepositive patients, to evaluate the potential benefit from chemotherapy. In node-positive patients with ER-positive disease, use of the 21-gene recurrence score assay is based mainly on retrospective data. Data from the prospective trial (RxPONDER trial) is awaited. 39 In 1 retrospective study, use of the 21-gene recurrence score in nodepositive disease was shown to decrease the rate of recommendation for adjuvant chemotherapy from 81% to 50%. 40 The West German Plan B prospective trial showed excellent 3-year survival of patients with a recurrence score 11 treated without chemotherapy and included patients with node-positive disease. 41 One of the major limitations of this study is that the patients enrolled in Z1071 were a heterogeneous cohort and were not selected based on tumor subtype. There was no standardized chemotherapy regimen recommended and although RCB reporting was recommended in the protocol it was not completed in a significant proportion (24%) of patients. The follow-up time is relatively short with an average follow-up of 4 years at the time of this report and additional follow-up is awaited. Additionally, the tumor subtyping is based on approximated subtype using receptor status reported from the local pathology laboratory and not based on central pathology review or molecular analysis of the individual tumors. A large proportion of patients enrolled had HR-positive/HER2-negative disease and practice patterns have shifted toward more use of endocrine therapy in these patients and less chemotherapy. Since HR-positive/HER2-negative tumors have lower pCR rates and longer time to recurrence, the high proportion of these patients in the study limits the interpretation of impact of RCB. We did observe higher rates of RCB-III than previously reported, raising the possibility of overestimation; however, this may be attributable to the fact that all patients enrolled in Z1071 were clinically node-positive at the time of diagnosis.
In summary, neoadjuvant chemotherapy is effective at achieving pCR in a substantial proportion of patients with HER2-positive and TNBC. For HER2-positive disease treated with chemotherapy and HER2-targeted therapy, 5-year BCSS and OS are excellent, regardless of response to therapy. For patients with chemotherapyresistant TNBC, with residual disease after neoadjuvant chemotherapy, alternative strategies should and are being explored to improve patient outcome.
ClinicalTrials.gov: NCT00881361. 
DISCUSSANTS Dr Monica Morrow (New York, NY):
Thank you. I congratulate Dr Boughey and her colleagues for using data from the ACOSOG Z1071, which was an important study examining the feasibility of sentinel node biopsy after neoadjuvant chemotherapy in patients presenting with nodal disease. They have used this data set to confirm the findings of earlier studies done examining different types of chemotherapy to look at the relationship between pathologic complete response, breast cancer subtype, and survival, and have demonstrated that using a variety of modern systemic therapy, pathologic complete response remains a predictor of good outcome, that rates of pathologic complete response vary by breast cancer subtype-being highest in the HER2 positive and lowest in the ER positive HER2-negative patients-and that the extent of residual disease is a predictor of outcome whether you measure it in a simple way by simply looking at residual tumor and nodes, or whether you measure it using the residual cancer burden score.
I have 3 questions. You saw no difference in breast cancerspecific survival in the 204 HER2-positive patients, whether or not they achieved pathologic complete response. In contrast, in the Cortazar meta-analysis of neoadjuvant trials which included 2000 HER2 overexpressing patients, there was a very strong relationship between pathologic complete response and outcome, but only half of those patients received HER2 blockade. So, do you believe that the availability of HER2 targeted agents has changed the fundamental relationship between pathologic complete response and outcome for this subset of patients? Or was your study simply underpowered to demonstrate this difference?
Second, in the triple-negative subset, you showed us convincingly that failure to achieve pathologic complete responses was associated with an increased rate of death. As you are aware, the CREATEX study has shown that adding capecitabine out back to patients who do not have pathologic complete response improves survival. Do you think it is time to adopt those results into practice now?
And then, finally, the ER-positive subset. We have known for a long time that pathologic complete response is extremely uncommon to neoadjuvant chemotherapy in ER-positive patients. And, as you have shown us, survival really is not very good in those who failed to obtain pathologic complete response. It is tempting to speculate that that is because we are delaying the therapy they need, which is longterm endocrine therapy.
So, do you think that the era of giving neoadjuvant chemotherapy to ER-positive patients simply on the basis of positive nodes is over, and that we should only do that if we select those patients with either molecular predictors or clinical surrogates for the luminal B subtype who are likely to respond?
I congratulate you again on this nice study.
Dr Judy C. Boughey (Rochester, MN):
Thank you, Dr Morrow, for your excellent discussion. In terms of your first question regarding HER2-positive patients, this study was designed and powered to address the primary surgical endpoint of the false negative rate of SLN surgery in this setting. So the data presented here on the HER2-positive population is hypothesis generating but would need further evaluation in larger cohorts.
I do think that the results are encouraging. As you mentioned, for HER2-positive breast cancer, there has definitely been a huge change from when we first identified this subtype, as an aggressive subtype of breast cancer, to now, when we have targeted therapy and see excellent responses in these patients with the use of HER2-directed therapy. Additionally, since Z1071 was conducted, we are now using dual agent targeted HER2 therapy more frequently, which is anticipated to further improve patient outcomes and could impact some of the results presented today.
It may well be that response in the HER2-positive patient at surgery doesn't give us the complete story because these patients go on to complete a year of directed HER2 therapy, and 9 months of that is usually given after surgery. We will need information from other larger studies and longer follow-up from studies such as this to definitively address this question.
Regarding your question about triple-negative breast cancer patients, taking the results of this study together with the larger body of literature, it's pretty clear that patients that have residual disease after neoadjuvant chemotherapy for triple-negative breast cancer are a group at high risk of future breast cancer events, where we need to be considering further systemic treatment. Capecitabine may be 1 potential option in those patients, and there are many ongoing trials looking at different agents in this setting. So I think in the future it's very likely that additional systemic therapy will become part of the clinical standard for patients with high risk residual disease. At this point I'm supporting the ongoing clinical trials in this area and continuing to watch this space as it evolves.
In terms of management of patients with estrogen receptor positive, HER2-negative disease, I agree with you, especially for the luminal A patients, that either endocrine therapy followed by surgical resection or surgical resection first (followed by endocrine therapy) is probably the optimal treatment for those patients.
I do like the approach that has been taken with the ACOSOG Z1031 and the Alternate trial through the Alliance for Clinical Trials in Oncology of treating patients with strongly estrogen receptor positive tumors with endocrine therapy, and then biopsying the tumor on treatment to see whether the endocrine therapy is shutting down the tumor proliferation. This allows us to potentially identify those tumors which are relatively endocrine resistant and consider those for chemotherapy, but also avoid chemotherapy for those patients whose tumors are endocrine responsive and have a good response to neoadjuvant endocrine therapy.
We are still learning the best treatment modality for estrogen receptor positive, HER2-negative breast cancer. Other areas are being explored such as the mTOR pathway, PI3 kinase pathway, CDK 4/6 inhibitors. I think we still have a lot of opportunity to have better targeted therapy for those patients that may allow us to step further away from chemotherapy. Thank you.
Dr Kirby Bland (Birmingham, AL):
Thank you. Dr Boughey, you and your colleagues are to be congratulated on this excellent study and for bringing it to the association and presenting this data.
My questions really reside on the types of chemotherapy and targeted therapy utilized. As you see here, your 5-year breast cancerspecific survival, 5-year survival, was highest within the HER2/neupositive cohort. I assume most of those received pertuzumab as your principal agent of therapy, and then is followed by the hormonal receptor positive HER2-negative patients. And that D.F.S. was 80%.
And finally, your triple negatives were the lowest survival rates, 5-year, and that was 75% as would be expected in most of the literature. That is the worst population that we treat for the nonbreast surgeons here, really that do poorly, and particularly in the young African American.
So the question, 6 different groups here treating this, medical oncologists are directing this therapy, I presume, in a uniform manner, but would you give us some details on the chemotherapeutic protocols, or can you do this from your data? And I'm particularly interested in knowing if a hormonally positive patient, HER2 negative, present with a large tumor, a stage 2 or a 3 lesion, would you consider using only hormonal therapy in those patients, or do you always have insistence on applying the chemotherapeutic protocol together with the hormonal therapy in that population?
I enjoyed this article very much.
Dr Judy C. Boughey (Rochester, MN):
Thank you very much. So the patients with HER2-positive disease on this trial, all received systemic neoadjuvant chemotherapy along with trastuzumab. This trial was actually conducted prior to the approval of pertuzumab (Perjeta). So none of these patients received pertuzumab. So definitely in the current day, most of these patients would receive chemotherapy, trastuzumab, and pertuzumab. That's definitely been a change in the practice between the years of this trial and current day.
In terms of the systemic chemotherapy used, this was very much a surgically written and focused trial. We allowed patients on the study who had received neoadjuvant chemotherapy and there was no specific regimen or length of treatment that was required.
Regarding your question related to the hormone receptor positive HER2-negative patients, in the era of this trial we were using neoadjuvant chemotherapy far more commonly for those patients as reflected by the fact that 46% of the patients in this study had hormone receptor-positive, HER2-negative disease. I think over the last several years, we've seen a change in that where increasingly now we would consider those patients for neoadjuvant endocrine therapy rather than neoadjuvant chemotherapy. So I would think if we were conducting this trial in the current era, we would see a higher proportion of triple-negative breast cancer and HER2-positive breast cancer and use of chemotherapy in the hormone receptor-positive HER2-negative disease being reserved for those patients with tumors with high Ki 67, high grade disease and large tumors.
Dr Frederick Greene (Charlotte, NC):
Judy, thank you for a beautifully presented study and for highlighting the work of the 8th Edition of the AJCC TNM staging classification. I would urge everyone to use our ''y'' descriptor when denoting the use of neoadjuvant therapy and to include this designation into clinical records and cancer patient abstracts.
We know that the time course between the end of neoadjuvant therapy and surgical resection is important in some sites, especially rectal cancer. Have we been able to look at the time course in this particular process and to evaluate the effect on overall survival for breast cancer?
Dr Judy C. Boughey (Rochester, MN):
That's not something that we have been able to tease out from this data set since, on the surgical study, we required that surgery was performed within 12 weeks of completion of chemotherapy because we did want to avoid too much wide variation in that factor, so unfortunately, we can't address that question from this data set.
Dr Nipun Merchant (Miami, FL):
As a non-breast-cancer surgeon, I'm very envious of the studies that you're able to do well-conducted studies, with large numbers of patients, different histologic subtypes, and now longterm follow-up. I think moving forward in cancer care, we're going to see neoadjuvant therapy being employed even more. You have this invaluable resource now in which you have pretreatment biopsies of patients, assessment of complete response and long-term outcome and biopsies of tumor specimens of residual disease after treatment.
So my question is, is there now an ongoing effort to sequence and profile these pre-and posttreatment tumor samples to identify biomarkers of response for pathologic CR, or lack of response, and then take this information to the next level and develop clinical trials tailoring therapies based on these biomarkers of response? Dr Judy C. Boughey (Rochester, MN):
That is an excellent point, and I definitely think moving forward that is the way that all clinical trials across all disease sites should be conducted and the way that we really can learn the most from these patients that participate in these trials. Unfortunately on 1071, although patients had biopsies of their nodes done at the local site, that tissue was not collected centrally. In many of the trials, it's a challenge to fund the tissue collection and storage.
Within this trial, we have not had the ability to look at that. We have done some work at my institution, Mayo Clinic. We enrolled 140 patients on a study and obtained preneoadjuvant chemotherapy tumor biopsies and postchemotherapy surgical biopsy samples and performed genome sequencing and established patient derived xenografts, and have been studying that information to try to identify key drivers of response to chemotherapy and chemotherapy resistance.
